Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.32 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.32 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.31 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.30 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543887 | 0.75 | — | — | |
| SCHEMBL4711813 | 0.75 | — | — | |
| SCHEMBL861270 | 0.74 | MEN1 (0.33) | MEN1KMT2ACYP2D6CYP19A1 | |
| SCHEMBL10832743 | 0.74 | MEN1 (0.33) | MEN1KMT2ACYP2D6CYP19A1 | |
| SCHEMBL361322 | 0.73 | MEN1 (0.35) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL2547791 | 0.73 | FDPS (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1234462 | 0.73 | MEN1 (0.32) | MEN1KMT2ACYP2D6CYP19A1 | |
| SCHEMBL7135901 | 0.73 | MEN1 (0.32) | MEN1KMT2ACYP2D6CYP19A1 | |
| Formic Acid SCHEMBL11465604 | 0.71 | CHRM5 (0.35) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL1819138 | 0.70 | CHRM2 (0.34) | MEN1KMT2AOPRD1CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499144-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499129-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2403847-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011058109-A1 | FUSED BICYCLIC PYRROLE AND IMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058111-A1 | AMINOPURINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058108-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058110-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010100405-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-09-10 | — | — | WO | disclosed |